Boston Common Asset Management LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 133,128 shares of the biopharmaceutical company's stock after purchasing an additional 17,146 shares during the quarter. Boston Common Asset Management LLC's holdings in Gilead Sciences were worth $14,917,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. HHM Wealth Advisors LLC grew its position in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $28,000. Crews Bank & Trust acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $31,000. Stephens Consulting LLC lifted its holdings in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC boosted its position in Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 216 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.
Gilead Sciences Trading Down 1.4%
Shares of Gilead Sciences stock traded down $1.49 on Monday, reaching $108.59. 6,570,283 shares of the company were exchanged, compared to its average volume of 8,898,922. The stock has a fifty day moving average price of $105.49 and a 200-day moving average price of $100.90. The firm has a market capitalization of $135.08 billion, a price-to-earnings ratio of 293.54, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a fifty-two week low of $62.69 and a fifty-two week high of $119.96.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same period in the previous year, the firm earned ($1.32) earnings per share. Gilead Sciences's revenue for the quarter was down .3% compared to the same quarter last year. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.91%. Gilead Sciences's dividend payout ratio is 66.53%.
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider now owns 121,152 shares in the company, valued at $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $99.82, for a total value of $249,550.00. Following the completion of the transaction, the chief financial officer now owns 165,674 shares in the company, valued at $16,537,578.68. This trade represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,929 shares of company stock worth $5,644,780 over the last 90 days. 0.27% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
A number of research analysts recently issued reports on GILD shares. Bank of America boosted their price objective on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Piper Sandler boosted their price objective on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. The Goldman Sachs Group lifted their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Finally, BMO Capital Markets lifted their target price on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.
View Our Latest Report on GILD
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
